Pyrimidines - Pharmacology
Research News and Information

Sunday, November 22, 2009

Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model.

29 Nov 2009 Stage 4 neuroblastoma (NB) is a devastating childhood cancer whose poor outcome has remained essentially unchanged in the last 20 years. Receptor tyrosine kinases have important roles in the control of proliferation, differentiation and apoptosis of ... Read more...

Kinetic mechanism and inhibitor characterization of WNK1 kinase.

Nov 2009 Pseudohypoaldosteronism type II (PHAII) is caused by the mutation of two members of the WNK (with-no-K[Lys] kinase) kinase family. We describe here the development of an in vitro WNK1 microfluidic mobility shift assay for kinetic mechanism studies. ... Read more...

RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information.

6 Oct 2009 Pyrimidinol carboxylic acids were designed as inhibitors of HIV-1 RNase H function. These molecules can coordinate to two divalent metal ions in the RNase H active site. Inhibition of enzymatic activity was measured in a biochemical assay, but no ... Read more...

Latest indexed articles for 'Pyrimidines - Pharmacology'

These are the very latest articles for this heading:

• Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cells in vitro and in orthotopic mouse model. 29 Nov 2009
• Kinetic mechanism and inhibitor characterization of WNK1 kinase. Nov 2009
• RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. 6 Oct 2009
• Sensitivity to azoxystrobin in Didymella bryoniae isolates collected before and after field use of strobilurin fungicides. 29 Sep 2009
• Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. 25 Sep 2009
• MMR/c-Abl-dependent activation of ING2/p73alpha signaling regulates the cell death response to N-methyl-N'-nitro-N-nitrosoguanidine. 15 Sep 2009
• Pharmacological modifications of the stretch-induced effects on ventricular fibrillation in perfused rabbit hearts. 9 Sep 2009
• Absence of adenosine-mediated aortic relaxation in A(2A) adenosine receptor knockout mice. 9 Sep 2009
• PPARalpha ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression. 9 Sep 2009
• Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. 30 Aug 2009
• In vitro susceptibility patterns of Aspergillus and Fusarium species isolated from equine ulcerative keratomycosis cases in the midwestern and southern United States with inclusion of the new antifungal agent voriconazole. 30 Aug 2009
• Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. 30 Aug 2009
• The effects of an hsp90 inhibitor on the paradoxical effect. 30 Aug 2009
• Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. 30 Aug 2009
• Novel pathway of endothelin-1 and reactive oxygen species in coronary vasospasm with endothelial dysfunction. 30 Aug 2009
• Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. 30 Aug 2009
• CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt. 30 Aug 2009
• Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. 30 Aug 2009
• Role of Rac 1 and cAMP in endothelial barrier stabilization and thrombin-induced barrier breakdown. 30 Aug 2009
• Bidirectional control of spike timing by GABA(A) receptor-mediated inhibition during theta oscillation in CA1 pyramidal neurons. 24 Aug 2009

See a longer list of these articles.

Technical information about 'Pyrimidines'

Definition: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.

Registry Number: 0

Descriptor UI: D011743

Alternative terms: Pyrimidines;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; biosynthesis;

Tree Number: D03.383.742;

Online Note: use PYRIMIDINES to search THONZYLAMINE 1972-84 (as Prov 1972)

History Note: THONZYLAMINE was heading 1972-84 (Prov 1972)